1. Nyce JW. Detection of a novel, primate-specific ‘kill switch’ tumor suppression mechanism that may fundamentally control cancer risk in humans: an unexpected twist in the basic biology of TP53. Endocr Relat Cancer 2018;25:R497-517.

2. Cornish-Bowden A. Why is uncompetitive inhibition so rare? A possible explanation, with implications for the design of drugs and pesticides. FEBS Letters 1986;203:3-6.

3. Nyce JW. Species-specific mechanisms of tumor suppression are fundamental drivers of vertebrate speciation: critical implications for the ‘war on cancer’. Endocr Relat Cancer 2019;26:C1-5.

4. Gordon GB, Newitt JA, Shantz LM, Weng DE, Talalay P. Inhibition of the conversion of 3T3 fibroblast clones to adipocytes by dehydroepiandrosterone and related anticarcinogenic steroids. Cancer Res 1986;46:3389-95.

5. Labrie F, Bélanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997;82:2396-402.

6. Kalogera E, Pistos C, Provatopoulou X, Athanaselis S, Spiliopoulou C, et al. Androgen glucuronides analysis by liquid chromatography tandem-mass spectrometry: could it raise new perspectives in the diagnostic field of hormone-dependent malignancies? J Chromatogr B Analyt Technol Biomed Life Sci 2013;940:24-34.

7. Anh NH, Long NP, Kim SJ, Min JE, Yoon SJ, et al. Steroidomics for the prevention, assessment, and management of cancers: a systematic review and functional analysis. Metabolites 2019;9:E199.

8. Yano A, Kagawa M, Takeshita H, Okada Y, Morozumi M, et al. Initial 3-month dynamics of dehydroepiandrosterone sulfate can predict responsiveness to primary androgen deprivation therapy in patients with metastatic prostate cancer. Asian J Androl 2019;21:635-6.

9. Wu Y, Tang L, Azabdaftari G, Pop E, Smith GJ. Adrenal androgens rescue prostatic dihydrotestosterone production and growth of prostate cancer cells after castration. Mol Cell Endocrinol 2019;486:79-88.

10. Penning TM. Dehydroepiandrosterone (DHEA)-SO4 depot and castration-resistant prostate cancer. Vitam Horm 2018;108:309-31.

11. Arakawa H, Nakanishi T, Yanagihara C, Nishimoto T, Wakayama T, et al. Enhanced expression of organic anion transporting polypeptides (OATPs) in androgen receptor-positive prostate cancer cells: possible role of OATP1A2 in adaptive cell growth under androgen-depleted conditions. Biochem Pharmacol 2012;84:1070-7.

12. Green S, Kaipainen A, Bullock K, Zhang A, Lucas J, et al. Role of OATP transporters in steroid uptake by prostate cancer cells in vivo. Prostate Cancer Prostatic Dis 2017;20:20-7.

13. Pizzagalli F, Varga Z, Huber RD, Folkers G, Meier PJ, et al. Identification of novel inhibitors of the steroid sulfate carrier ‘sodium-dependent organic anion transporter’ SOAT (SLC10A6) by pharmacophore modelling. Mol Cell Endocrinol 2016;428:133-41.

14. Green S, Kaipainen A, Bullock K, Zhang A, Lucas J, et al. Role of OATP transporters in steroid uptake by prostate cancer cells in vivo. Prostate Cancer Prostatic Dis 2017;20:20-7.

15. Lee WM, Jang KS, Bae J, Koh AR. The role of steroid sulfatase as a prognostic factor in patients with endometrial cancer. Yonsei Med J 2016;57:754-60.

16. Mungenast F, Aust S, Vergote I, Vanderstichele A, Sehouli J, et al. Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. Oncol Lett 2017;13:4047-54.

17. Daśko M, Demkowicz S, Biernacki K, Harrous A, Rachon J, et al. Novel steroid sulfatase inhibitors based on N-thiophosphorylated 3-(4-aminophenyl)-coumarin-7-O-sulfamates. Drug Dev Res 2019;80.

18. Daśko M, Przybyłowska M, Rachon J, Masłyk M, Kubiński K, et al. Synthesis and biological evaluation of fluorinated N-benzoyl and N-phenylacetoyl derivatives of 3-(4-aminophenyl)-coumarin-7-O-sulfamate as steroid sulfatase inhibitors. Eur J Med Chem 2017;128:79-87.

19. Sang X, Han H, Poirier D, Lin SX. Steroid sulfatase inhibition success and limitation in breast cancer clinical assays: an underlying mechanism. J Steroid Biochem Mol Biol 2018;183:80-93.

20. Ciolino HP, MacDonald CJ, Yeh GC. Inhibition of carcinogen-activating enzymes by 16alpha-fluoro-5-androsten-17-one. Cancer Res 2002;62:3685-90.

21. Malik AS, Narayan RK, Wendling WW, Cole RW, Pashko LL, et al. A novel dehydroepiandrosterone analog improves functional recovery in a rat traumatic brain injury model. J Neurotrauma 2003;20:463-76.

22. Burgess JP, Green JS, Hill JM, Zhan Q, Lindeblad L, et al. Identification of [14C]Fluasterone metabolites in urine and feces collected from dogs after subcutaneous and oral administration of [14C]Fluasterone. Drug Metab Dispos 2009;37:1089-97.

23. Lindeblad MO, Bauer KS, Zakharov AD, Hill JM, Green JS, et al. Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes. Chem Biol Interact 2010;183:317-26.

24. Schwartz AG, Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 2004;3:171-87.

25. Schwartz AG, Pashko LL. Potential therapeutic use of dehydroepiandrosterone and structural analogs. Diabetes Technol Ther 2001;3:221-4.

26. Peña L, Silván G, Pérez-Alenza MD, Nieto A, Illera JC. Steroid hormone profile of canine inflammatory mammary carcinoma: a preliminary study. J Steroid Biochem Mol Biol 2003;84:211-6.

27. Zhu X, Wu S, Yuan X, Wang H, Ma C. Progression free survival related to 18F-FDG PET/CT uptake and 131I uptake in lung metastases of differentiated thyroid cancer. Hell J Nucl Med 2019;22:123-30.

28. Duan Y, Li J, Zhang Y, Wang W, Sun X, et al. Comparison of primary tumour volumes delineated on four-dimensional computed tomography maximum intensity projection and (18) F-fluorodeoxyglucose positron emission tomography computed tomography images of non-small cell lung cancer. J Med Imaging Radiat Oncol 2015;9:623-30.

29. Pietri E, Massa I, Bravaccini S, Ravaioli S, Tumedei MM, et al. Phase II study of dehydroepiandrosterone in androgen receptor-positive metastatic breast cancer. Oncologist 2019;24:743-e205.

30. Boral D, Marchetti D. Liquid biopsy in prostate cancer: a case for comprehensive genomic characterization of circulating tumor cells. Clin Chem 2018;64:251-3.

31. Ankney JA, Xie L, Wrobel JA, Wang L, Chen X. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients. BMC Med Genomics 2019;12:78.

32. Keup C, Mach P, Aktas B, Tewes M, Kolberg HC, et al. RNA profiles of circulating tumor cells and extracellular vesicles for therapy stratification of metastatic breast cancer patients. Clin Chem 2018;64:1054-62.

33. Shen J, Kong W, Wu Y, Ren H, Wei J, et al. Plasma mRNA as liquid biopsy predicts chemo-sensitivity in advanced gastric cancer patients. J Cancer 2017;8:434-42.

34. Shen J, Wei J, Guan W, Wang H, Ding Y, et al. Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. J Transl Med 2014;12:355.

35. Nyce J. A lex naturalis delineates components of a human-specific, adrenal androgen-mediated, p53-dependent, "kill switch" tumor suppression mechanism. Endocr Relat Cancer 2019;Epub ahead of print.

Cancer Drug Resistance
ISSN 2578-532X (Online)


All published articles will preserved here permanently:


All published articles will preserved here permanently: